Abstract
Objective:
To characterize the patient population utilizing circulating cell-free fetal DNA (ccffDNA) testing at a large academic center and evaluate trends in the performance of invasive diagnostic procedures.
Study design:
A retrospective cohort study of all patients who underwent cell-free DNA testing from May to December 2012 was performed.
Result:
During the study period, 206 patients had cell-free DNA testing. Of those, 75% (155/206) were of ages ⩾35 years. Of those undergoing ccffDNA testing, 41% had positive aneuploidy screening and 38% had abnormal ultrasound findings. Only 7% of the patients with negative ccffDNA testing opted for an invasive diagnostic procedure compared with 60% with positive testing (P<0.01). The rate of invasive procedures decreased from 5.9% of all visits to the center during a similar 8-month period in 2010 to 4.1% of all visits during the study period (P<0.01).
Conclusion:
Our data suggest that ccffDNA testing leads to reduced uptake of invasive procedures.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350 (9076): 485–487.
Chiu RW, Akolekar R, Zheng YW, Leung TY, Sun H, Chan KC et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 2011; 342: c7401.
Ehrich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagasan L, Tim R et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011; 204 (3): 205.e1–11.
Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011; 13 (11): 913–920.
Sparks AB, Wang ET, Struble CA, Barrett W, Stokowski R, McBride C et al. Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. Prenat Diagn 2012; 32 (1): 3–9.
Norton ME, Brar H, Weiss J, Karimi A, Laurent LC, Caughey AB et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 207 (2): 137.e1–e8.
Nicolaides KH, Syngelaki A, Gil M, Atanasova V, Markova D . Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. Prenat Diagn 2013; 33 (6): 575–579.
American College of Obstetricians and Gynecologists Committee on Genetics. Committee Opinion No. 545: Noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 2012; 120 (6): 1532–1534.
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 88, December 2007. Invasive prenatal testing for aneuploidy. Obstet Gynecol 2007; 110 (6): 1459–1467.
Eddleman KA, Malone FD, Sullivan L, Dukes K, Berkowitz RL, Kharbutli Y et al. Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol 2006; 108 (5): 1067–1072.
Zaretsky M, Hickman A, McIntire D . The impact on maternal fetal medicine practice procedures after implementation of non-invasive aneuploidy screening by circulating cell-free DNA analysis. Am J Obstet Gynecol 2013; 208 (1): S253.
Chetty S, Garabedian MJ, Norton ME . Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenat Diagn 2013; 33 (6): 542–546.
Bombard AT . Circulating Cell-Free Nucleic Acid Technology: Noninvasive Prenatal Testing for Fetal Aneuploidies. The NIPT Consortium Meeting: Yokohama, Japan, 2013.
Gil MM, Quezada MS, Bregant B, Ferraro M, Nicolaides KH . Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies. Ultrasound Obstet Gynecol 2013; 42 (1): 34–40.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM . First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol 2013; 42 (1): 41–50.
Benacerraf BR, Harlow B, Frigoletto FD Jr . Are choroid plexus cysts an indication for second-trimester amniocentesis? Am J Obstet Gynecol 1990; 162 (4): 1001–1006.
Dagklis T, Plasencia W, Maiz N, Duarte L, Nicolaides KH . Choroid plexus cyst, intracardiac echogenic focus, hyperechogenic bowel and hydronephrosis in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks. Ultrasound Obstet Gynecol 2008; 31 (2): 132–135.
Agathokleous M, Chaveeva P, Poon LC, Kosinski P, Nicolaides KH . Meta-analysis of second-trimester markers for trisomy 21. Ultrasound Obstet Gynecol 2013; 41 (3): 247–261.
Kaijomaa M, Ulander VM, Ryynanen M, Stefanovic V . The significance of the second trimester sonographic soft markers in pregnancies after normal first trimester screening. Prenat Diagn 2013; 33 (8): 804–806.
Wapner RJ, Martin CL, Levy B, Ballif BC, Eng CM, Zachary JM et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med 2012; 367 (23): 2175–2184.
Palomaki GE, Deciu C, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med 2012; 14 (3): 296–305.
Ashoor G, Syngelaki A, Poon LC, Rezende JC, Nicolaides KH . Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol 2013; 41 (1): 26–32.
Poon LC, Musci T, Song K, Syngelaki A, Nicolaides KH . Maternal Plasma Cell-Free Fetal and Maternal DNA at 11-13 Weeks’ Gestation: Relation to Fetal and Maternal Characteristics and Pregnancy Outcomes. Fetal Diagn Ther 2013; 33 (4): 215–223.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
ADH and LK have previously been paid consultants for the Sequenom Center for Molecular Medicine (San Diego, CA). The remaining authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Pettit, K., Hull, A., Korty, L. et al. The utilization of circulating cell-free fetal DNA testing and decrease in invasive diagnostic procedures: an institutional experience. J Perinatol 34, 750–753 (2014). https://doi.org/10.1038/jp.2014.102
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jp.2014.102
This article is cited by
-
NIPT and Informed Consent: an Assessment of Patient Understanding of a Negative NIPT Result
Journal of Genetic Counseling (2016)
-
Positive predictive value of non-invasive prenatal screening for fetal chromosome disorders using cell-free DNA in maternal serum: independent clinical experience of a tertiary referral center
BMC Medicine (2015)